Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib.
Front Oncol. 2023 Mar 17;13:1125021. doi: 10.3389/fonc.2023.1125021. eCollection 2023.
Front Oncol. 2023.
PMID: 37007122
Free PMC article.
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P, Lajoie L, Mallavialle A, Alcaraz LB, Mansouri H, Fenou L, Garambois V, Rubio L, David T, Coenon L, Boissière-Michot F, Chateau MC, Ngo G, Jarlier M, Villalba M, Martineau P, Laurent-Matha V, Roger P, Guiu S, Chardès T, Gros L, Liaudet-Coopman E.
Desroys du Roure P, et al. Among authors: fenou l.
J Immunother Cancer. 2024 Jan 30;12(1):e007135. doi: 10.1136/jitc-2023-007135.
J Immunother Cancer. 2024.
PMID: 38290768
Free PMC article.
Item in Clipboard
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, Jacot W, Sardet C, Theillet C.
Orhan E, et al. Among authors: fenou l.
Cancer Lett. 2024 May 1;589:216820. doi: 10.1016/j.canlet.2024.216820. Epub 2024 Apr 3.
Cancer Lett. 2024.
PMID: 38574883
Free article.
Item in Clipboard
Cite
Cite